Anwar Hashem

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6449427/publications.pdf

Version: 2024-02-01

212478 162838 3,636 87 28 57 citations h-index g-index papers 100 100 100 6555 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Middle East Respiratory Syndrome Coronavirus Infection Elicits Long-lasting Specific Antibody, T and B Cell Immune Responses in Recovered Individuals. Clinical Infectious Diseases, 2023, 76, e308-e318.	2.9	6
2	Low clinical utility of testing for antiâ€platelet factor 4 in asymptomatic individuals after ChAdOx1 nCoVâ€19 vaccine. International Journal of Laboratory Hematology, 2022, 44, 424-429.	0.7	8
3	Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies. Vaccines, 2022, 10, 151.	2.1	6
4	SARS-CoV-2 genomes from Saudi Arabia implicate nucleocapsid mutations in host response and increased viral load. Nature Communications, 2022, 13, 601.	5 . 8	40
5	David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors. MAbs, 2022, 14, 2057832.	2.6	7
6	Amplifying Lateral Flow Assay Signals for Rapid Detection of COVIDâ€19 Specific Antibodies. Global Challenges, 2022, 6, .	1.8	6
7	Seroprevalence of COVID-19 in Riyadh city during the early increase of COVID-19 infections in Saudi Arabia, June 2020. Saudi Journal of Biological Sciences, 2022, 29, 103282.	1.8	1
8	Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients. Journal of Clinical Medicine, 2022, 11, 3093.	1.0	0
9	Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice. Human Vaccines and Immunotherapeutics, $2022, 18, \ldots$	1.4	1
10	Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115273.	0.8	61
11	A Robust, Safe, and Scalable Magnetic Nanoparticle Workflow for RNA Extraction of Pathogens from Clinical and Wastewater Samples. Global Challenges, 2021, 5, 2000068.	1.8	10
12	Quick and Easy Assembly of a One-Step qRT-PCR Kit for COVID-19 Diagnostics Using In-House Enzymes. ACS Omega, 2021, 6, 7374-7386.	1.6	5
13	Simultaneous detection and mutation surveillance of SARS-CoV-2 and multiple respiratory viruses by rapid field-deployable sequencing. Med, 2021, 2, 689-700.e4.	2.2	16
14	Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia. Journal of Infection and Public Health, 2021, 14, 832-838.	1.9	27
15	Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia. Viruses, 2021, 13, 1413.	1.5	16
16	Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1. Vaccines, 2021, 9, 852.	2.1	8
17	Synthetic SARS-CoV-2 Spike-Based DNA Vaccine Elicits Robust and Long-Lasting Th1 Humoral and Cellular Immunity in Mice. Frontiers in Microbiology, 2021, 12, 727455.	1.5	10
18	Iron Chelation Reduces DNA Damage in Sickle Cell Anemia. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110472.	0.7	1

#	Article	IF	CITATIONS
19	Targeted Inhibition of Fibroblast Growth Factor Receptor 1-GLI Through AZD4547 and GANT61 Modulates Breast Cancer Progression. Frontiers in Cell and Developmental Biology, 2021, 9, 758400.	1.8	2
20	Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages. IScience, 2021, 24, 103328.	1.9	4
21	Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia. Vaccines, 2021, 9, 1297.	2.1	33
22	Community-Based Seroprevalence of SARS-CoV-2 Antibodies following the First Wave of the COVID-19 Pandemic in Jazan Province, Saudi Arabia. International Journal of Environmental Research and Public Health, 2021, 18, 12451.	1.2	9
23	DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model. Frontiers in Immunology, 2021, 12, 785349.	2.2	7
24	iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. Virus Research, 2020, 288, 198129.	1.1	226
25	Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay. Frontiers in Microbiology, 2020, 11, 2020.	1.5	45
26	SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients. Scientific Reports, 2020, 10, 16561.	1.6	84
27	Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Frontiers in Immunology, 2020, 11, 1986.	2.2	146
28	Performance of Commercially Available Rapid Serological Assays for the Detection of SARS-CoV-2 Antibodies. Pathogens, 2020, 9, 1067.	1.2	7
29	Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. Viruses, 2020, 12, 1390.	1.5	42
30	The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target. International Journal of Molecular Sciences, 2020, 21, 3544.	1.8	219
31	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel Medicine and Infectious Disease, 2020, 35, 101735.	1.5	94
32	Cross-sectional prevalence study of MERS-CoV in local and imported dromedary camels in Saudi Arabia, 2016-2018. PLoS ONE, 2020, 15, e0232790.	1.1	11
33	Seroprevalence of MERS-CoV in healthy adults in western Saudi Arabia, 2011–2016. Journal of Infection and Public Health, 2020, 13, 697-703.	1.9	17
34	Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera. Methods in Molecular Biology, 2020, 2099, 117-126.	0.4	16
35	Quantification of the Middle East Respiratory Syndrome-Coronavirus RNA in Tissues by Quantitative Real-Time RT-PCR. Methods in Molecular Biology, 2020, 2099, 99-106.	0.4	5
36	Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay. Methods in Molecular Biology, 2020, 2099, 107-116.	0.4	36

#	Article	IF	Citations
37	Comparative metagenomics and characterization of antimicrobial resistance genes in pasteurized and homemade fermented Arabian laban. Food Research International, 2020, 137, 109639.	2.9	11
38	Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experience. Journal of Infection and Public Health, 2020, 13, 834-838.	1.9	250
39	Qualitative and Quantitative Determination of MERS-CoV S1-Specific Antibodies Using ELISA. Methods in Molecular Biology, 2020, 2099, 127-133.	0.4	1
40	Title is missing!. , 2020, 15, e0232790.		0
41	Title is missing!. , 2020, 15, e0232790.		0
42	Title is missing!. , 2020, 15, e0232790.		0
43	Title is missing!. , 2020, 15, e0232790.		0
44	Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels. Scientific Reports, 2019, 9, 16292.	1.6	72
45	Amotosalen and ultraviolet A light efficiently inactivate MERSâ€coronavirus in human platelet concentrates. Transfusion Medicine, 2019, 29, 434-441.	0.5	32
46	Molecular Evidence of Influenza A Virus Circulation in African Dromedary Camels Imported to Saudi Arabia, 2017–2018. Open Forum Infectious Diseases, 2019, 6, ofz370.	0.4	6
47	Development and validation of different indirect ELISAs for MERS-CoV serological testing. Journal of Immunological Methods, 2019, 466, 41-46.	0.6	26
48	Taxonomic diversity of antimicrobial-resistant bacteria and genes in the Red Sea coast. Science of the Total Environment, 2019, 677, 474-483.	3.9	23
49	Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine. Frontiers in Immunology, 2019, 10, 597.	2,2	9
50	A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model. Journal of Infectious Diseases, 2019, 220, 1558-1567.	1.9	64
51	Development and validation of different indirect ELISAs for MERS-CoV serological testing. Journal of Infection and Public Health, 2019, 12, 142.	1.9	0
52	MERS oV, influenza and other respiratory viruses among symptomatic pilgrims during 2014 Hajj season. Journal of Medical Virology, 2019, 91, 911-917.	2.5	24
53	Enzootic patterns of Middle East respiratory syndrome coronavirus in imported African and local Arabian dromedary camels: a prospective genomic study. Lancet Planetary Health, The, 2019, 3, e521-e528.	5.1	52
54	Prevalence of human papillomavirus in Jeddah, Saudi Arabia. Annals of Saudi Medicine, 2019, 39, 403-409.	0.5	12

#	Article	IF	Citations
55	Diversity of dengue virus-3 genotype III in Jeddah, Saudi Arabia. Acta Tropica, 2018, 183, 114-118.	0.9	6
56	Dengue infection in patients with febrile illness and its relationship to climate factors: A case study in the city of Jeddah, Saudi Arabia, for the period 2010–2014. Acta Tropica, 2018, 181, 105-111.	0.9	7
57	Genetic characterization and diversity of circulating influenza A/H1N1pdm09 viruses isolated in Jeddah, Saudi Arabia between 2014 and 2015. Archives of Virology, 2018, 163, 1219-1230.	0.9	7
58	First complete genome sequence of circulating dengue virus serotype 3 in Jeddah, Saudi Arabia. New Microbes and New Infections, 2018, 21, 9-11.	0.8	2
59	Inactivation of Middle East respiratory syndromeâ€coronavirus in human plasma using amotosalen and ultraviolet A light. Transfusion, 2018, 58, 52-59.	0.8	39
60	No molecular evidence of MERS-CoV circulation in Jeddah, Saudi Arabia between 2010–2012: a single-center retrospective study. Journal of Infection in Developing Countries, 2018, 12, 390-393.	0.5	1
61	Phylogenetic characterization of circulating Dengue and Alkhumra Hemorrhagic Fever viruses in western Saudi Arabia and lack of evidence of Zika virus in the region: A retrospective study, 2010â€2015. Journal of Medical Virology, 2017, 89, 1339-1346.	2.5	15
62	Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein. Scientific Reports, 2017, 7, 44875.	1.6	91
63	Patterns of Human Respiratory Viruses and Lack of MERS-Coronavirus in Patients with Acute Upper Respiratory Tract Infections in Southwestern Province of Saudi Arabia. Advances in Virology, 2017, 2017, 1-7.	0.5	17
64	Susceptibility of influenza viruses circulating in Western Saudi Arabia to neuraminidase inhibitors. Journal of King Abdulaziz University, Islamic Economics, 2016, 37, 461-465.	0.5	3
65	Multiple Introductions of Dengue 2 Virus Strains into Saudi Arabia from 1992 to 2014. Vector-Borne and Zoonotic Diseases, 2016, 16, 391-399.	0.6	21
66	Influenza immunization and surveillance in Saudi Arabia. Annals of Thoracic Medicine, 2016, 11, 161.	0.7	6
67	Prospects of HA-Based Universal Influenza Vaccine. BioMed Research International, 2015, 2015, 1-12.	0.9	36
68	Development and applications of universal H7 subtype-specific antibodies for the analysis of influenza H7N9 vaccines. Vaccine, 2015, 33, 1129-1134.	1.7	10
69	Complete genome sequencing and phylogenetic analysis of dengue type 1 virus isolated from Jeddah, Saudi Arabia. Virology Journal, $2015,12,1.$	1.4	143
70	Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine. Human Vaccines and Immunotherapeutics, 2015, 11, 1351-1356.	1.4	9
71	Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes. Mucosal Immunology, 2015, 8, 211-220.	2.7	41
72	Evidence for Camel-to-Human Transmission of MERS Coronavirus. New England Journal of Medicine, 2014, 370, 2499-2505.	13.9	736

#	Article	IF	CITATIONS
73	Detection of the Middle East Respiratory Syndrome Coronavirus Genome in an Air Sample Originating from a Camel Barn Owned by an Infected Patient. MBio, 2014, 5, e01450-14.	1.8	89
74	Evidence for Camel-to-Human Transmission of MERS Coronavirus. New England Journal of Medicine, 2014, 371, 1359-1360.	13.9	89
75	A universal monoclonal antibody protects against all influenza A and B viruses by targeting a highly conserved epitope in the viral neuraminidase. BMC Genomics, 2014, 15, P8.	1.2	1
76	CD40 Ligand Preferentially Modulates Immune Response and Enhances Protection against Influenza Virus. Journal of Immunology, 2014, 193, 722-734.	0.4	35
77	Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Research, 2013, 100, 567-574.	1.9	95
78	A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. Biochemical and Biophysical Research Communications, 2013, 441, 226-229.	1.0	45
79	The Universal Epitope of Influenza A Viral Neuraminidase Fundamentally Contributes to Enzyme Activity and Viral Replication. Journal of Biological Chemistry, 2013, 288, 18283-18289.	1.6	25
80	A Novel Synthetic Receptor-Based Immunoassay for Influenza Vaccine Quantification. PLoS ONE, 2013, 8, e55428.	1.1	22
81	Subcutaneous immunization with recombinant adenovirus expressing influenza A nucleoprotein protects mice against lethal viral challenge. Human Vaccines and Immunotherapeutics, 2012, 8, 425-430.	1.4	18
82	Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using Universal Antibodies in Simple Slot Blot Assays. Journal of Visualized Experiments, 2011, , .	0.2	12
83	The effect of interferon-α on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicology and Applied Pharmacology, 2011, 253, 130-136.	1.3	14
84	Recent Developments in Bioinformatics Analyses of Influenza A Virus Surface Glycoproteins and their Biological Relevance. Current Bioinformatics, 2011, 6, 415-426.	0.7	11
85	Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochemical and Biophysical Research Communications, 2010, 403, 247-251.	1.0	48
86	Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine, 2010, 28, 5774-5784.	1.7	59
87	Aurintricarboxylic Acid Is a Potent Inhibitor of Influenza A and B Virus Neuraminidases. PLoS ONE, 2009, 4, e8350.	1.1	48